Abstract 384P
Background
Microsatellite instability (MSI)test has been found and developed with relationship of HNPCC or Lynch syndrome. Its role has been extended from screening marker for Lynch syndrome detection to response marker for immune checkpoint therapy. We investigated to know prevalence of abnormal microsatellite instability (MSI-L/H) among endometrial cancer ovary cancer.
Methods
We identified 51 cases of MSI samples from ovary and endometrial cancer visiting hereditary gynecologic cancer center.
Results
We found 34 ovary cancer ,13 endometrial cancer and 4 colon cancer patients. Median age was 56.6(18∼78). About thirty percent have family cancer history among patient relatives (14/45(31.1%)). Early stage cancer (I∼II) (4/25,16.0%) have higher incidence than late stage cancer (III∼IV) (2/28,7.1%). Abnormal MSI have three serous type and endometrioid type pathology. Among abnormal MSI, we found two MSI-L and four MSI-H (6/51(11.8%)). We found one MSI-H ovary cancer ,3 MSI-H endometrial cancer patients (1/34(2.9%),3/13(23.1%)).
Conclusions
There are about 10 percent of abnormal MSI in this study group. Prospective large clinical study is needed for hereditary cancer prevention and precision medicine.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract